A Report From the 42nd Annual Meeting of the International Continence Society (October 15-19 – Beijing, China).

A report from the 42nd Annual Meeting of the International Continence Society (October 15-19 – Beijing, China).

Filed under: Drug and Alcohol Rehabilitation

Drugs Today (Barc). 2012 Nov; 48(11): 741-51
Rabasseda X

As Beijing was selected as the site for this year’s International Continence Society (ICS) meeting, crowds of locals navigating through the subway train lines and tourists lining up for access to the Forbidden City and other landmarks were joined by a less numerous but a still significant number of researchers, scientists and practitioners working on urinary tract diseases and disorders going to the China National Convention Center to attend the podium and poster sessions. Located next to the Bird’s Nest Olympic stadium and offering grand views over the Olympic park from the upper floor where non-discussion posters were displayed, the modern facilities allowed for a smooth, seamless meeting during which a number of highly relevant new findings were discussed. The following report summarizes selected presentations on pharmacotherapy and drug candidates for overactive bladder and other common diseases of the urinary tract.
HubMed – drug


Latest advances in biomarker discovery and development.

Filed under: Drug and Alcohol Rehabilitation

Drugs Today (Barc). 2012 Nov; 48(11): 735-9
Tracy M

Oxford Global’s 7th Annual Biomarkers Congress, held February 21-22, 2012, in Manchester (UK), gathered together approximately 300 delegates and speakers with a specific interest in biomarkers and their application in the field of drug discovery and development, as well as their enabling technologies. The audience and participants came from diverse and mixed backgrounds, from academicians and industry business professionals to representatives of solutions providers and CROs offering services in the field of biomarker assay development and sample analysis. Focus was broad, including all types of biomarkers and their application, i.e., prognostic and diagnostic markers, predictive markers, patient selection strategies in drug development, point-of-care solutions, pharmacodynamic and target engagement biomarkers as well as safety-related approaches. There were presentations spanning the entire range of biomarker development, from discovery to clinical qualification and analytical validation of a specific marker or a markers panel. A wide range of therapeutic areas were also covered; however, the fields of oncology and inflammatory diseases were more prominent, since they currently provide best case studies for biomarker discovery and clinical utility.
HubMed – drug


Vandetanib therapy in medullary thyroid cancer.

Filed under: Drug and Alcohol Rehabilitation

Drugs Today (Barc). 2012 Nov; 48(11): 723-33
Grabowski P, Briest F, Baum RP, Zaknun JJ, Kulkarni HR, Zeitz M, Hörsch D

The U.S. Food and Drug Administration (FDA) approved vandetanib in April 2011 for the treatment of unresectable, locally advanced or metastatic medullary thyroid cancer (MTC). In Europe it was approved in March 2012, but only for the treatment of aggressive and symptomatic MTC. This small molecule is a tyrosine kinase inhibitor of several growth factors involved in cellular proliferation and angiogenesis, including the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor receptors 2 and 3 (VEGFR-2, VEGFR-3). In addition, vandetanib is an inhibitor of the RET (rearranged during transfection) gene, a proto-oncogene often mutated in familial MTC. Since MTC is a rare disease, for which no previous medical therapies are approved, vandetanib is the first drug shown to be effective in a large phase III trial treating patients with metastatic or locally advanced MTC. Common adverse events are diarrhea, nausea, hypertension, headache and QT prolongation that are manageable and are commonly outweighed by the benefits of vandetanib in terms of delaying disease progression and inducing tumor response.
HubMed – drug



I’m So Vain I Probably Think This DVD Is About Us – This is the sequel to “I’m So Vain I Probably Think This DVD Is About Me.” Three years after that event, my son and I attended the 2010 Crossroads Guitar Festival. We were lucky enough to be on the front row! We were so close that my son caught both the white cloth and the Chicago Blackhawks flag that Bill Murray threw out. Once again, I have watched the officially released DVD and culled the best clips that feature the two of us. I have done the work, so you don’t have to! This time, I decided against my own commentary. My apologies to Babs! Note: The real purpose of the Crossroads Guitar Festivals is to raise money for drug and alcohol rehabilitation. This spoof is not intended to make light of that.


Related Drug And Alcohol Rehabilitation Information…